|1.||Grachev, Igor D: 5 articles (08/2014 - 11/2013)|
|2.||Tolosa, Eduardo: 4 articles (08/2014 - 10/2004)|
|3.||Ramírez, J: 3 articles (01/2015 - 01/2014)|
|4.||Górriz, J M: 3 articles (01/2015 - 01/2014)|
|5.||Walker, Zuzana: 3 articles (08/2014 - 11/2007)|
|6.||Hauser, Robert A: 3 articles (08/2014 - 11/2013)|
|7.||Bajaj, Nin: 3 articles (08/2014 - 11/2013)|
|8.||Minoshima, Satoshi: 2 articles (03/2015 - 09/2014)|
|9.||Khedher, L: 2 articles (01/2015 - 01/2015)|
|10.||Salas-Gonzalez, D: 2 articles (01/2015 - 01/2015)|
01/01/2014 - "Is ioflupane I123 injection diagnostically effective in patients with movement disorders and dementia? "
08/01/2014 - "The different study designs offered an assortment of variables to assess the effects on the diagnostic performance of (123)I-ioflupane: on-site versus 3-5 blinded image readers, number of image evaluations, early/uncertain versus late/confirmed clinical diagnosis as reference standard, and subjects with movement disorders versus dementia. "
01/01/2014 - "To pool clinical trials of similar design to assess overall sensitivity and specificity of ioflupane I123 injection (DaTSCAN or ioflupane ((123)I)) to detect or exclude a striatal dopaminergic deficit disorder (SDDD), such as parkinsonian syndrome and dementia with Lewy bodies. "
08/01/2014 - "Individual-reader diagnostic performance and between-reader agreement in assessment of subjects with Parkinsonian syndrome or dementia using 123I-ioflupane injection (DaTscan) imaging."
01/01/2014 - "Ioflupane ((123)I) imaging has the potential to improve diagnostic accuracy in patients with signs and symptoms of a movement disorder and/or dementia. "
|2.||Movement Disorders (Movement Disorder)
11/01/2015 - "Thirty-nine ET patients with and without parkinsonian features and 13 HC underwent detailed examination by a movement disorders neurologist and 123-I ioflupane SPECT. "
09/01/2009 - "[Negative predictive value of SPECT with I123 ioflupane in movement disorders (reply)]."
01/01/2009 - "A non-degenerative etiology is supported by a normal SPI [normal SPECT with 123I-Ioflupane (SPI)] in a patient with movement disorders (MD). "
01/01/2009 - "[Negative predictive value of (123)I Ioflupane SPECT in movement disorders]."
05/01/2007 - "Initial clinical experience with [123I]ioflupane scintigraphy in movement disorders."
|3.||Parkinsonian Disorders (Parkinsonism)
03/01/2015 - "Brain SPECT was performed in 39 patients with parkinsonian syndrome (age 61 ± 15 years, 18 male patients) 4 hours after IV injection of 3 to 5 mCi 123I ioflupane using SPECT-CT acquisition. "
02/01/2015 - "Further research is warranted to evaluate differences in I-ioflupane uptake patterns among the various parkinsonian syndromes. "
02/01/2015 - "Atypical Parkinsonian syndromes with very poor striatal uptake on 123I-ioflupane SPECT imaging."
01/01/2015 - "Comparison between Different Intensity Normalization Methods in 123I-Ioflupane Imaging for the Automatic Detection of Parkinsonism."
01/01/2015 - "Correction: Comparison between Different Intensity Normalization Methods in 123I-Ioflupane Imaging for the Automatic Detection of Parkinsonism."
|4.||Parkinson Disease (Parkinson's Disease)
09/13/2008 - "The aim of this study is to evaluate substantia nigra echogenicity in a group of Parkinson's disease patients and controls and compare with disease and functional neuroimaging parameters using ioflupane-single photon emission computed tomography (SPECT). "
05/01/2007 - "Seventeen patients (ten women, seven men; age range 44-84 years) with a presumptive diagnosis of Parkinson's disease (PD) were referred for single-photon emission computed tomography (SPECT) scintigraphy using [(123)I]ioflupane between November 2002 and August 2003. "
01/15/2010 - "To unveil cognitive-nigrostriatal correlations in Parkinson's disease (PD), 30 de novo, drug-naïve PD patients and 15 patients with essential tremor (Controls, CTR) underwent a neuropsychological (NPS) battery and brain SPECT with [I-123]Ioflupane, as a biomarker of nigrostriatal function. "
01/01/2007 - "Previous 123-I ioflupane SPECT (DaTSCAN) studies involving radioisotope labeling of the dopamine transporter protein at presynaptic level in patients with IPD (idiopathic Parkinson's disease) have found this technique to be highly sensitive in exploring the nigrostriatal pathway. "
12/01/2014 - "Brain single-photon-emission-computerized tomography (SPECT) with I-ioflupane (I-FP-CIT) is useful to diagnose Parkinson disease (PD). "
10/30/2012 - "Clinical, morphologic (brain MRI, (123)I-ioflupane SPECT), and neurophysiologic (tremor recording, nerve conduction studies) study in 22 patients with FXTAS, including 4 women. "
01/01/2014 - "Strongest diagnostic performance of ioflupane [(123)I] imaging for clinical diagnosis of Parkinson's syndrome (PS) or non-PS was associated with tremor and balanced motor dominance rather than with BRP dominance. "
01/01/2014 - "Diagnostic effectiveness of ioflupane [(123)I] imaging was high in all subgroups: 91% to 100% for H&Y low (<2) and high (≥2) stage subjects; 93% to 96% for MMSE low (<29) or high (≥29) scores; 91% to100% in both age subgroups (younger [<68] and older [≥68]); and 92% to 100% in subjects with both tremor dominant and balanced motor signs. "
03/15/2008 - "Mean disease duration was 6.5 +/- 3 years, 61.5% of patients had a positive family history of tremor, 73% did not need drug treatment, performance of 123I-Ioflupane SPECT showed reduced striatal tracer uptake in 65.4% of patients, and odor identification testing was pathologic in all the patients tested (n = 22). "
08/01/2013 - "Early abnormalities in 123I-ioflupane (DaTSCAN) imaging in the fragile X-associated tremor ataxia syndrome (FXTAS): a case report."
|1.||Dopamine Plasma Membrane Transport Proteins (Dopamine Transporter)
|2.||2- carbomethoxy- 8- (3- fluoropropyl)- 3- (4- iodophenyl)tropane
|4.||Dopamine Receptors (Dopamine Receptor)
|5.||Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)
|6.||Biological Markers (Surrogate Marker)
|9.||diazenedicarboxylic acid bis(N'-methylpiperazide)